Mo3e is a protease-sensitive membrane antigen (p75,50) selectively expressed by human monocytic cells (monocytes and U-937 cells) stimulated in vitro by exposure to a variety of activating factors, including phorbol diester compounds, bacterial lipopolysaccharide (LPS), and muramyl dipeptide (MDP) (R. F. Todd et al., J. Immunol. 135,3869,1985). Here we report that primary and multiply-passaged cultures of HUVEC also express the Mo3e determinant after stimulation by phorbol myristate acetate (PMA) and related inducers of protein kinase C. As measured in a radioimmunoassay of anti-Mo3e antibody binding to monolayer cultures of HUVEC, unstimulated cells bore little if any Mo3e. After culture for 4-120 hr in medium containing PMA, 4fl-phorbol dibutyrate, 4&phorbol didecanoate, or mezerein (each at a concentration of 8 1 nM), or 1 -oleoyl-2-acetoyl-sn-3glycerol(l mM), HUVEC were found to selectively express the Mo3e determinant. The magnitude of expression was dependent upon the concentration ofthe stimulus, maximal by 24 hr, and inhibited by cycloheximide. The combination of PMA and the calcium ionophore, ionomycin, had an additive or synergistic effect on HUVEC Mo3e expression. The biologically inactive phorbol compounds rl&phorbol and 4~ phorbol didecanoate failed to stimulate Mo3e expression. Also inactive as inducers of HUVEC Mo3e expression were crude lymphokine and monokine supematants, recombinant human lymphokines (interferon-y and interleukin-2), recombinant human monokines (interleukin-1 and tumor necrosis factor), bacterial cell wall products including LPS and MDP, pharmacologic agents that increase intracellular cyclic adenosine monophosphate (prostaglandin Er, cholera toxin, theophylline, isoproterenol and isobutylmethylxanthine), lectins (Con A and PHA), and heparin. These results indicate that Mo3e is an inducible plasma membrane antigen of not only mononuclear phagocytes but also cultured HUVEC. o 1988 Academic her, IX.
INTRODUCTION
Cells of the mononuclear phagocyte system and endothelial cells display a number of similar physiological characteristics that include the capacity to ingest soluble and particulate matter (pinocytosis and phagocytosis, respectively) ( 1, 2) , to present anti-genie material to T lymphocytes in association with plasma membrane Ia (class II) histocompatability determinants (3) (4) (5) (6) , and to synthesize and secrete certain soluble inflammatory mediators such as interleukin-1 (IL-l)" (7) (8) (9) . The performance of these and other functional activities by mononuclear phagocytes and endothelial cells is up-regulated by exposure to a variety of inflammatory activating factors in vitro or in vivo (1, 5, 8, 9) . The physiologic "activation" of macrophages and endothelial cells is often manifest by changes in morphology, metabolic activity, and plasma membrane composition. For example, exposure of human monocytes or human umbilical vein endothelial cells (HUVEC) to interferon-y (IFN-y) in vitro stimulates the surface expression of Ia determinants ( lo-14) . Other changes in plasma membrane phenotype that occur as a consequence of activation include the enhanced surface expression of Fc receptors by interferon-stimulated human monocytes ( 15, 16) or by endothelial cells after cytomegalovirus (CMV) infection (17) ICAM-1 (a molecule promoting cellular adhesion) by U-937 monoblasts stimulated with phorbol myristate acetate (PMA) (18) and by HUVEC exposed to IL-1, IFN-r or tumor necrosis factor (TNF) ( 18, 19) , and membrane-bound tissue factor (procoagulant activity) by human monocytes (20, 2 1) and HUVEC cultured in medium containing TNF (22, 23) , IL-l (24) (25) (26) (27) , or bacterial lipopolysaccharide (LPS) (24, 25, 27) .
The application of hybridoma-generated monoclonal antibody technology has led to the identification of additional activation associated plasma membrane determinants expressed by mononuclear phagocytes and/or endothelial cells. In the mononuclear phagocyte system these include the acquired expression of the ACM. 1 (28) , Asialo GM1 (29) , 7/4 (30), MAA-(3 I), and MA158.2 (32, 33) antigenic determinants by murine macrophages activated in vivo (by BCG or Cornyebacterium parvum inoculation) or in vitro (by lymphokines), and the expression of the Al-3 (34, 35) and Mo3e (36) antigens by human mononuclear phagocytes exposed to soluble-activating factors (LPS, PMA, IFN-7) in vitro. Likewise, Pober and his colleagues have demonstrated the expression of H4/ 18 by HUVEC activated in vitro by exposure to IL-1, TNF, and LPS (37, 38) .
With the goal of further characterizing the plasma membrane consequences of human mononuclear phagocyte activation, we previously generated a murine monoclonal antibody specific for an antigen, Mo3e (p75,50), expressed by human monocytes stimulated in vitro by exposure to soluble-activating factors including LPS, PMA, and MDP (36) . In this report, we have demonstrated that surface Mo3e expression is also selectively acquired by HUVEC cultured in medium containing PMA and certain other compounds known to stimulate the activation of protein kinase C. ' Abbreviations used: BSA, bovine serum albumin; CMV, cytomegalovirus; Con A, concanavalin A; cpm, counts per minute; DPBS, Dulbecco's phosphate-buffered saline; ECGS, endothelial cell growth supplement; HUVEC, human umbilical vein endothelial cells; IL-1, interleukin-1; IFN-7, interferon-y; LPS, Escherichia coli lipopolysaccharide; LPS-MCM, lipopolysaccharide-stimulated monocyte-conditioned medium; MDP, muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoghttamine); MEZ, mezerein; NGS, normal goat serum; NP-40, Nonidet P-40 detergent; OAG, L-cr-1-oleoyl-2-acetoyl-sn-3-glycerol; PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PHA, phytohemagglutinin; PHA-LCM, phytohemagglutinin-stimulated lymphocyte-conditioned medium; 4BPDB, 4fi-phorbol 12,13-dibutyrate; 4aPDD, 4cu-phorbol 12,13-didecanoate; 4@PDD, 4@-phorbol 12,13didecanoate; PMA, phorbol my&ate acetate (4&phorbol 12-myristate-13-acetate); RIA, radioimmunoassay; TNF, tumor necrosis factor a; 1640-AS, RPM1 1640 medium supplemented with 10% autologous serum; MIF, migration inhibitory factor.
MATERIALS AND METHODS
Media and reagents. The following media and tissue culture additives were purchased from GIBCO Laboratories (Grand Island, NY): Medium 199 with 25 mM Hepes buffer, Hanks' salts and L-glutamine (380-2350); 200 mM L-glutamine (320-5030); penicillin-streptomycin solution (600-570); 1-X trypsin-EDTA (6 10-5300); RPM1 1640 (320-1875). The following reagents were purchased from Sigma Chemical Co. (St. Louis, MO): 4fi-phorbol (P8893); 4/3-phorbol 12,13-dibutyrate (4PPDB, P 1269); 4@-phorbol 12,13-didecanoate (4PPDD, P90 18); 4cy-phorbol 12,13-didecanoate (4aPDD, P80 14); 4&phorbol 12-myristate 13-acetate (PMA, P8 139); dimethyl sulfoxide (DMSO, D5879); Escherichia coli LPS (L2755); phytohemagglutinin (PHA, L8504); cholera toxin (C30 12); 3-isobutyl-I-methylxanthine (IBMX; 15879); concanavalin A (Con A, C2010); cycloheximide (C6255); theophylline (T1633); isoproterenol(I5627); bovine serum albumin (BSA, A4503); diaminobenzidine (DAB, D800 1); and Histopaque ( 1077-1). Mezerein (MEZ, M4600) was purchased from LC Services Corp. (Woburn, MA). L-cu-1 -Oleoyl-2-acetoyl-sn-3 glycerol (OAG, 800 100) was purchased from Avanti Polar Lipids, Inc. (Birmingham, AL). Ionomycin from Streptomycin conglobatus (407952) was purchased from Calbiochem (San Diego, CA). Ultrapure IL-1 (GUPI-1) was purchased from Genzyme (Boston, MA). Porcine heparin (1000 u/ml, 2440-4 1) was purchased from Elkins-Sinn, Inc. PMA, 4PPDB, 4PPDD, 4aPDD, 4&phorbol, MEZ, and OAG were initially diluted in DMSO to make stock solutions of 1 mg/ml which were stored at -80°C. Ionomycin was kept as a 4 n04 solution in DMSO and stored at -80°C.
Antibodies used. The generation and characterization of murine monoclonal antibodies anti-MO 1 (anti-CD1 lb, IgG2a, clone 44) (39), anti-MO1 (anti-CD1 lb, IgM, clone 17) (40), anti-MO2 (anti-CD14, IgG2b, clone 26) (4 l), anti-Mo3e (IgM, clone 109) (36), anti-13 (anti-Ia, IgG2a, clone 9-49) (42), and anti&M (anti-HLA-A, B, C, IgG2b, clone 88) (43) have previously been described. The anti-&M was a generous gift of Dr. Lee Nadler of the Dana-Farber Cancer Institute (Boston, MA). Monoclonal antibodies were diluted 1: 100 in Dulbecco's phosphate-buffered saline (DPBS) with 1% BSA and 0.1% glucose (radioimmunoassay buffer (RIA-buffer)). Polyclonal '251-labeled sheep F(ab')2 anti-mouse immunoglobulin fragments (12?-SAM Ig) were purchased from DuPont, NEN Products (NEX-162, Boston, MA) and used after dilution in RIA-buffer to a final stock concentration of 2.5 X lo6 cpm/ml. Endothelial cell cultures. HUVEC were harvested from normal term delivery human umbilical cords by the method of Gimbrone et al. (44) and were serially propogated according to the protocol of Maciag et al. (45) as modified by Weiss and Regiani (46) in which endothelial cells were cultured in 20% pooled human serum. Except where indicated, HUVEC were propogated in Costar (Cambridge, MA) 24-well plates which had been precoated with a 0.2% gelatin solution. For the majority of experiments, primary and first-passage cultures were employed. In selected experiments, multiply-passaged cells were used (up to the sixth passage). At the time of passage, HUVEC monolayers were disrupted into single cell suspensions using trypsin-EDTA and then seeded onto fresh gelatin-coated plates. Cultures were fed three times weekly (complete medium change) with growth medium consisting of M 199 containing 20% pooled human serum, 100 u/ml penicillin, 100 u/ml streptomycin, 2.5 pg/ml amphotericin B, and 150 pg/ml ECGS.
When confluent (4-6 days after seeding), 2.0-cm2 HUVEC monolayer cultures containing 0.5 ml of growth medium were stimulated by the addition of various soluble factors in 5-to loo-p1 volumes. For additives initially dissolved in DMSO, ethanol, or methanol, the final solvent concentration did not exceed 0.5, 0.2, or 0.3%, respectively. In most experiments, HUVEC were subsequently cultured for an additional 24 hr at 37°C in a humidified atmosphere of 5% COZ in air prior to RIA. In other experiments, HUVEC were cultured for varying lengths of time up to 120 hr.
In selected experiments, HUVEC were seeded in gelatin-coated 35-mm culture dishes (Falcon Plastic Division of Becton-Dickinson Laboratories, Lincoln Park, NJ), and when confluent, cultured in the presence of stimulating factors as indicated above.
Monocyte-conditioned medium. Peripheral blood mononuclear cells (PBMC) were isolated by Histopaque-1077 density gradient centrifugation (47) of heparin-anticoagulated blood (4 u/ml) from healthy volunteer donors. Monocyte-rich adherent cells were obtained by incubating PBMC in 1640-AS (RPM1 1640 medium supplemented with 10% autologous serum) on loo-mm plastic culture dishes (Falcon Plastics, Oxnard, CA) pretreated with autologous serum (48) . After 60 min at 37°C nonadherent PBMC were aspirated off, and the plates were washed with five changes of 37°C HBSS (5 ml each wash). After washing, the monocyte cultures were fed with 5 ml of 1640-AS and cultured with 50 rig/ml LPS for 72 hr at 37°C in a humidified atmosphere of 5% CO2 in air. The supernatant medium was then harvested by aspiration, filtered (0.22 pm), and stored at -80°C until use.
Radioimmunoassay. In experiments designed to measure monoclonal antibody binding to 2.0-cm2 monolayer cultures of HUVEC, an indirect RIA was employed (all steps carried out at 4°C): The medium was removed sequentially from each well and 200 ~1 of a 1: 100 (saturating) dilution of the primary mouse monoclonal antibody was added to each well and allowed to incubate for 30 min. For each experimental antibody an isotype-identical negative control monoclonal antibody was run in parallel as a measure of nonspecific antibody binding. The primary antibody was then removed and each well was sequentially rinsed twice with 300 ~1 of RIA buffer prior to the addition of 200 ~1 of 12?-SAM Ig containing 5 X 1 O5 cpm. After a second 30-min incubation, "'I-SAM Ig was removed and each well was rinsed three times with 300 ~1 RIA-buffer solution. After the last wash the HUVEC cultures were solubilized by the addition of 400 ~1 DPBS containing 1% Nonidet P-40 (NP-40) and al-lowed to incubate for 1 hr at room temperature. The cell lysates were then transferred to 8 X 75mm plastic tubes for counting in a TM-Analytic Gamma Trac 119 1 gamma scintillation counter (Elk Grove Village, IL). Specific 1251-SAM Ig binding was calculated by subtracting the mean counts per minute (cpm) of triplicate cultures exposed to the negative control monoclonal antibody (generally IgM anti-MO 1) from that of triplicate cultures exposed to the experimental antibody (generally IgM anti-Mo3e).
In selected experiments, HUVEC monolayers were fixed prior to RIA according to the following protocol: medium was removed and the monolayers were incubated in 300 ~1 of PBS containing 10% formaldehyde for 10 min at 4°C. The monolayers were washed three times by the addition of 300 ~1 PBS and then incubated in 300 ~1 of a 1: 1 solution of methanol:3% H202 in water for 10 min at 4°C. After three additional washes in PBS, the cells were subjected to RIA as above.
Zmmunoperoxiduse assay. Immunocytochemical localization of antibody binding was carried out by a modification of the immunoperoxidase avidin-biotin complex technique (ABC method) described by Hsu et al. (49) using a Vectastain ABC kit (mouse IgM No. PK-40 10) purchased from Vector Labs (Burlington, CA). All steps were carried out at room temperature. Confluent monolayers of HUVEC grown on 35-mm culture dishes were incubated in growth medium containing 50 rig/ml PMA or control medium for 24 hr prior to fixation as detailed in the preceding paragraph. The plates were washed three times with 2 ml of PBS and then incubated for 10 min in 2 ml of PBS containing 6% normal goat serum (NGS) and 4% BSA. The monolayers were then exposed to 750 ~1 of the primary monoclonal antibodies (diluted 1: 100 in PBS containing 1% NGS and 4% BSA) for 30 min, washed three times in PBS, and then exposed to 750 ~1 of the biotinylated goat anti-mouse IgM antibody (diluted 1:200 in PBS containing 1% NGS and 4% BSA) for 30 min. After an additional three washes in PBS, 750 ~1 of ABC reagent was then added to each plate. The plates were again incubated for 30 min, washed twice in PBS, and then exposed to 0.04% diaminobenzidine in PBS for 10 min. After two distilled HZ0 rinses, the plates were counterstained with hematoxylin and examined directly using an American Optical OneTwenty microscope.
RESULTS
As shown in Table 1 , exposure of primary cultures of HUVEC to PMA (50 rig/ml for 24 hr at 37°C) induced the expression of Mo3e as detected in a RIA measuring the binding of anti-Mo3e monoclonal antibody to monolayers of PMA-stimulated and unstimulated HUVEC. Surface Mo3e expression by unstimulated HUVEC (after subtraction of background antibody binding) was negative. To exclude the possibility that this increase in surface Mo3e was a manifestation of a generalized upmodulation of HUVEC plasma membrane components, we examined the binding of other monoclonal reagents specific for class I and II histocompatibility antigens &M and Ia, respectively), as well as selected isotype identical control reagents (anti-MO 1 and anti-Mo2) that identify myelomonocytic antigens not expressed by endothelial cells (50) (51) (52) . It can be seen that culture of HUVEC in media containing PMA did not affect the surface expression of class I or II histocompatibility antigens. Moreover, the increase in anti-Mo3e antibody binding to PMA-treated cells was not a consequence of an increase in the level of nonspecific antibody binding (as would be detected by an increase in the binding of anti-MO1 and anti-MO2 negative control antibodies). In addition, there was no significant difference in the number of viable endothelial cells per monolayer in PMA-stimulated and unstimulated HUVEC at the time of the assay (data not shown), excluding the possibility that such a numerical difference could account for the results observed. On the basis of these results (reproducible in over 80 experiments), we conclude that unstimulated HUVEC express negligible quantities of surface Mo3e but that exposure to PMA induces the selective acquisition of surface Mo3e expression not only by primary cultures of HUVEC but also by multiply passaged cells (up to six passages; data not shown).
By surface immunofluoresence analysis of unfixed PMA-stimulated HUVEC and by immunoperoxidase staining of formalin-fixed cells (data not shown), a diffuse pattern of Mo3e expression was observed, indicating that Mo3e expression by HUVEC is a feature shared by the vast majority of stimulated HUVEC.
As seen in Figs. 1 and 2 , the magnitude of surface Mo3e expression by PMA-stimulated HUVEC was directly related to the concentration of PMA and to the duration of stimulation. Peak Mo3e expression was observed at PMA concentrations exceeding 25 rig/ml (range 3-200 rig/ml) and after 14 hr of culture in media containing PMA (range 4-120 hr).
Since PMA is a stimulus of surface Mo3e expression by HUVEC, we then evaluated the stimulatory capacity of other related compounds that are known to activate protein kinase C in mammalian cells (reviewed in (53, 54) ). As shown in Fig. 3 , two other biologically active phorbol compounds, 4PPDD and 4/3PDB, stimulated the expression of surface Mo3e as did the related diterpene compound MEZ (55) . In contrast, the biologically inert cr stereoisomer of 4PPDD and the parent alcohol 48- (2 cm2) were cultured for 48 hr at 37°C; PMA (to make a final concentration of 50 r&ml) was added sequentially such that triplicate cultures were exposed to PMA for the indicated durations. In the "0-hr" duration cultures, PMA was added just prior to the RIA; "control" cultures received no PMA. As in Fig. 1 , the height of the bars represents the mean specific '251-SAM-Ig binding + SD. The subtracted nonspecific (anti-Mol) binding was 1455, 1746, 1713, 1596,2459, and 2225 (mean cpm, left to right). As in Fig. 1 , the addition of DMSO diluent alone had no effect on surface Mo3e expression. The results of this experiment are representative of those seen in three similar experiments. , and mezerein were all added such that the final concentration of each was 8 1 mt4 (equivalent to 50 rig/ml PMA, an appropriate control for the highest concentration of DMSO diluent to which the cells were exposed, 0.11% was included, as shown). As previously described (58), the OAG was added in 11 hourly doses to give a final concentration of 1 mM(OAG being rapidly degraded (56, 57) phorbol were inactive in stimulating Mo3e expression, These observations suggested a relationship between the capacity of these agents to stimulate the expression of Mo3e and their reported activity in stimulating protein kinase C activation (53, 54) . This notion was further supported by the stimulatory effect of the cell-permeable diacylglycerol compound OAG which can mimic the effect of endogenous 1,2-diacylglycerol in stimulating protein kinase C activity (56, 57) (Fig. 3) .
Because of reports demonstrating the synergistic effect of calcium ionophores and PMA in generating effector responses in other cellular systems (58-63), we then evaluated the combined stimulatory capacity of ionomycin and PMA to induce surface Mo3e expression by HUVEC. In Fig. 4 , it can be seen that ionomycin alone at a concentration of 1 PM had a modest stimulatory effect that was additive to that of PMA at the submaximally stimulatory concentrations of 5-10 rig/ml. In several experiments as represented by the data in Fig. 4 , ionomycin had a synergistic effect with PMA at the maximally stimulatory concentrations of 25-50 rig/ml. An increase in intracellular calcium induced by ionomycin may therefore promote surface Mo3e expression stimulated by PMA (5 3).
To determine if protein synthesis is required for the surface expression of Mo3e on HUVEC stimulated by PMA, we examined the effect of cycloheximide when added to HUVEC cultures at the start of their incubation with PMA. As shown in 
' HUVEC monolayers (2.0 cm2, primary cultures in Experiments 1 and 2; fifth-passage cultures in Experiment 3) were cultured in medium containing either PMA (50 rig/ml) or no additive (unstimulated) for 24 hr at 37'C. Parallel triplicate monolayers were then either formalin-fixed (see Materials and Methods) or left unfixed prior to RIA for the expression of Mo3e (as measured by specific 'ZSI-SAM Ig binding).
b Specific "'I-SAM Ig binding (mean cpm f SD of triplicate determinations). ' '251-SAM Ig binding (mean of triplicate determinations) to monolayers exposed to isotype-identical negative control reagent (anti-Mol), i.e., background binding. In Experiments 1 and 2, '251-SAM Ig binding to anti-Mo2treated monolayers (as an additional IgM-negative control) was nearly identical to that shown for anti- MO 1. toplasmic antigen. This conclusion was supported by the results of quantitative RIA in which significant levels of specific anti-Mo3e binding to fixed, unstimulated HU-VEC was detected ( Table 2 ). The greater magnitude of specific anti-Mo3e binding to fixed PMA-stimulated cells over that bound to fixed unstimulated HUVEC may indicate the synthesis of new antigen in addition to that found in pre-existing cytoplasmic pools.
As indicated in Table 3 , we evaluated the stimulatory activity of other soluble factors in addition to PMA that have been reported to either up-regulate endothelial cell and/or macrophage functional activity or to increase the surface expression of plasma membrane receptors and antigenic determinants: lymphokines and monokines (PHA-stimulated lymphocyte-conditioned media (PHA-LCM) (64), recombinant IFN-7 (5, 8-14, 18) IL-2 (65), LPS-stimulated monocyte-conditioned media (LPS-MCM) (7), IL-1 (18, 19, (24) (25) (26) (27) , TNF (19, 22, 23) ), bacterial cell wall products (LPS and MDP (24, 25, 27, 36) ), lectins (PHA (66) and Con-A (7)), drugs that raise the intracellular concentration of cyclic adenosine monophosphate (cyclic AMP) (cholera toxin, isoproterenol, theophylline, IBMX, and PGE-2 (67-70)), and heparin (endothelial cell growth stimulatory activity (7 1)). Whereas crude lymphokine and monokine supernatants, bacterial cell wall products, certain recombinant lymphokines, and monokines stimulated morphologic changes characteristic of those seen in HU-VEC monolayers stimulated by PMA (Table 3) there was no reproducible parallel stimulation of surface Mo3e expression by these factors when tested over broad concentration ranges and at exposures lasting from 4 to 72 hr. The only exception was a variable degree of low magnitude surface Mo3e expression stimulated by either PHA or PHA-LCM. LI Duration of culture period during which HUVEC monolayers were exposed to stimuli. b Degree to which monolayer cells exhibited a "whorling" morphology: ranging from (-), no shape changes observed, to (tt+) majority of monolayer cells exhibiting marked shape changes similar to that stimulated by PMA.
c Number of separate experiments performed. d Poorly reproducible, low-level expression of surface Mo3e induced.
DISCUSSION
Based upon previous studies involving human mononuclear phagocytes, Mo3e is a protease-sensitive antigen (~7550) that is selectively expressed by human monocytes and myelomonocytic cell lines after exposure in vitro to soluble activating factors that include PMA and certain other biologically active phorbol compounds, bacterial LPS, and MDP (72) . As shown in this report, the surface expression of Mo3e is also a feature characteristic of HUVEC stimulated by PMA and related compounds. Control experiments demonstrated that the acquisition of surface Mo3e expression was a selective response of PMA-stimulated HUVEC (the surface expression of HU-VEC class I and class II histocompatibility antigens being unaltered) and was not due to an increase in nonspecific monoclonal antibody binding or a relative increase in the number of PMA-stimulated cells. The specificity of anti-Mo3e antibody for PMA-stimulated HUVEC (as opposed to small numbers of contaminating leukocytes) was documented by visual examination of monolayers stained by immunofluoresence and immunoperoxidase techniques which showed a homogeneous pattern of expression. Since HUVEC cultured in the absence of PMA, like unstimulated human monocytes (36) macrophages within inflammatory foci (glomerulonephritis, allograft rejection, sarcoidosis, and appendicitis) of immunoperoxidase-stained frozen tissue sections. Among endothelial cells, capillary endothelium of normal ovary, lymph nodes, lung, and skin were weakly Mo3e positive but endothelial staining was more prominent in inflammatory specimens. Some Mo3e staining by "normal" macrophages and endothelial cells in these tissue specimens is consistent with our observation that there exists a sequestered pool of intracellular Mo3e detectable in fixed (permeabilized), unstimulated U-937 cells (73) and HUVEC (Table 2) .
While a "physiological" stimulus of HUVEC Mo3e expression has not as yet been identified (Table 3) , we suspect that expression of surface Mo3e by PMA-stimulated HUVEC is not an in vitro artifact. We base this conclusion on the selective stimulatory effects of PMA, 4PPDD, 4/3PDB, MEZ, and OAG, compounds which can mimic the effect of endogenous 1,2-diacylglycerol in activating protein kinase C (53, 54). The additive or synergistic effect of the calcium ionophore, ionomycin, and PMA suggests the additional contribution of intracellular calcium mobilization (59) (60) (61) (62) (63) to an activation process leading to surface Mo3e expression, These observations are therefore consistent with the notion that surface Mo3e expression by HUVEC is an effector response that depends upon protein kinase C activation and calcium mobilization stimulated by endogenous products of the phosphatidylinositol signal transduction pathway 1,2-diacylglycerol and inositol trisphosphate, respectively (53, 54) . As demonstrated in other biological systems, these products are generated by phosphatidylinositol hydrolysis stimulated by receptor-mediated ligand binding (53, 54) .
The quest for a "natural" ligand that is stimulatory of Mo3e expression in HUVEC is still in progress.
As shown in Table 4 , Mo3e expression by PMA-stimulated HUVEC is one of several plasma membrane phenotypic changes associated with exposure of HUVEC to soluble activating stimuli. Included among these changes is the expression of ICAM-1 ( 18, 19) , a 97-kDa adhesion-promoting molecule shared by human leukocytes (U-937, HL-60) (18) and endothelial cells cultured in the presence of PMA or certain natural cellular products of stimulated leukocytes (IL-1, IFN--y, or TNF) (19) . Its molecular weight and expression by lymphocytes clearly distinguish ICAM-from Mo3e (p75,50) (72). Also distinct from Mo3e is the H4/18 antigen (~100, 120) (37) which is a transient feature of HUVEC exposed to IL-1 or TNF (37) : its expression by HUVEC as measured by RIA reaches a peak at 3-6 hr of culture and then declines to undetectable baseline levels (37) . Other surface components whose activity or density is up-regulated by exposure to activating stimuli include endothelial cell procoagulant activity (stimulated in HUVEC by IL-1, TNF, or LPS (22) (23) (24) (25) 27) , class II histocompatibility antigens (stimulated in HUVEC by PHA and IFN--r (14, 66)) and Fc receptors (stimulated in bovine pulmonary endothelial cells by leukocyte-derived lysates or infection with CMV or influenza virus ( 17)).
The physiological significance of Mo3e expression by PMA-stimulated HUVEC is as yet unknown. We have previously reported that anti-Mo3e monoclonal antibody blocks the response of human monocytes to migration inhibitory factor (MIF), suggesting that Mo3e contributes to MIF responsiveness (74) . Whether Mo3e itself represents the surface receptor for MIF remains to be determined in direct ligand binding assays. What role Mo3e plays in the functional activity of endothelial cells is open to speculation but its capacity to promote the binding of MIF ligand by endothelial cells will be assessed.
